Binita Shah1, Jeffrey S Berger2, Nicole Allen1, Yu Guo3, Steven P Sedlis4, Jinfeng Xu3, Adriana Perez1, Michael Attubato1, James Slater1, Frederick Feit1. 1. Department of Medicine (Cardiology), NYU School of Medicine, New York, New York. 2. Department of Medicine (Cardiology and Hematology), NYU School of Medicine, New York, New York. 3. Department of Population Health (Biostatistics), NYU School of Medicine, New York, New York. 4. Department of Medicine (Cardiology), VA New York Harbor Health Care System, New York, New York.
Abstract
OBJECTIVE: To determine how two different types of iodinated contrast media (CM), low-osmolar ionic dimer ioxaglate (Hexabrix) and iso-osmolar non-ionic dimer iodixanol (Visipaque), affect multiple indices of hemostasis. BACKGROUND: In vitro models demonstrate differential effects of ionic and non-ionic CM on markers of hemostasis. METHODS: This blinded endpoint trial randomized 100 patients to ioxaglate oriodixanol. The primary endpoint was change in endogenous thrombin potential (ETP) following diagnostic angiography. Secondary endpoints included change in markers of fibrinolysis [tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1)] and platelet aggregation following diagnostic angiography and percutaneous coronary intervention (PCI) with bivalirudin. Data are presented as median [interquartile range]. RESULTS:ETP significantly decreased after diagnostic angiography in both ioxaglate (baseline 1810 nM*minute [1540-2089] to post-angiography 649 nM*minute [314-1347], p < 0.001) and iodixanol groups (baseline 1682 nM*minute [1534-2147] to post-angiography 681 nM*minute [229-1237], p < 0.001), but the decrease was not different between CM (p = 0.70). There was a significant increase in ETP during PCI (n = 45), despite the use of bivalirudin, suggesting a prothrombotic effect of PCI (post-angiography 764 nM*minute [286-1283] to post-PCI 1081 nM*minute [668-1552], p = 0.02). There were no significant differential effects on tPA, PAI-1, and markers of platelet activity. CONCLUSION: There were no significant differential effects between ioxaglate and iodixanol. Both CM led to significant reductions in thrombin generation and no significant effects on fibrinolytic activity or platelet activity, thereby contributing to a favorable antithrombotic milieu.
RCT Entities:
OBJECTIVE: To determine how two different types of iodinated contrast media (CM), low-osmolar ionic dimer ioxaglate (Hexabrix) and iso-osmolar non-ionic dimer iodixanol (Visipaque), affect multiple indices of hemostasis. BACKGROUND: In vitro models demonstrate differential effects of ionic and non-ionic CM on markers of hemostasis. METHODS: This blinded endpoint trial randomized 100 patients to ioxaglate or iodixanol. The primary endpoint was change in endogenous thrombin potential (ETP) following diagnostic angiography. Secondary endpoints included change in markers of fibrinolysis [tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1)] and platelet aggregation following diagnostic angiography and percutaneous coronary intervention (PCI) with bivalirudin. Data are presented as median [interquartile range]. RESULTS:ETP significantly decreased after diagnostic angiography in both ioxaglate (baseline 1810 nM*minute [1540-2089] to post-angiography 649 nM*minute [314-1347], p < 0.001) and iodixanol groups (baseline 1682 nM*minute [1534-2147] to post-angiography 681 nM*minute [229-1237], p < 0.001), but the decrease was not different between CM (p = 0.70). There was a significant increase in ETP during PCI (n = 45), despite the use of bivalirudin, suggesting a prothrombotic effect of PCI (post-angiography 764 nM*minute [286-1283] to post-PCI 1081 nM*minute [668-1552], p = 0.02). There were no significant differential effects on tPA, PAI-1, and markers of platelet activity. CONCLUSION: There were no significant differential effects between ioxaglate and iodixanol. Both CM led to significant reductions in thrombin generation and no significant effects on fibrinolytic activity or platelet activity, thereby contributing to a favorable antithrombotic milieu.
Authors: Andrew G C Sutton; Victoria J Ashton; Philip G Campbell; Dallas J A Price; James A Hall; Mark A de Belder Journal: Catheter Cardiovasc Interv Date: 2002-11 Impact factor: 2.692
Authors: K Takazoe; H Ogawa; H Yasue; T Sakamoto; H Soejima; Y Miyao; H Kawano; Y Moriyama; K Misumi; H Suefuji; K Kugiyama; M Yoshimura Journal: Ann Med Date: 2001-04 Impact factor: 4.709
Authors: Arvid Nordenhem; Karin Leander; Johan Hallqvist; Ulf de Faire; Margareta Sten-Linder; Björn Wiman Journal: Thromb Res Date: 2005-01-16 Impact factor: 3.944
Authors: H C Hemker; P Giesen; R AlDieri; V Regnault; E de Smed; R Wagenvoord; T Lecompte; S Béguin Journal: Pathophysiol Haemost Thromb Date: 2002 Sep-Dec